BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

South Korea’s AMI Pharm Reports Phase 2 Success of ‘AYP-101,’ a Potential New Leader in Nonsurgical Fat Reduction

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, H...

September 02, 2025 | News

Daiichi Sankyo Europe Initiates Development of Oral Triple Combination Tablets to Enhance LDL-C Management

Daiichi Sankyo Europe announced the initiation of the development of new oral triple combination tablets in Europe containing bempedoic acid, ezetimibe, an...

September 02, 2025 | News

Wegovy® Demonstrates Superior Cardiovascular Benefit Over Tirzepatide in Real-World Study

Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart atta...

September 01, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Sanofi and AstraZeneca’s Beyfortus Receives HSA Approval to Prevent RSV in Infants

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety ...

August 20, 2025 | Regulatory

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape

Invisible chemical impurities in medicines can pose very visible risks to patient safety and pharmaceutical reputations. In recent years, a quiet c...

August 19, 2025 | Analysis

China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus

The first seven months of 2025 saw robust dealmaking in China’s biopharma and healthcare sector, even as global headwinds tempered some activity. Chi...

August 15, 2025 | Report

Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...

August 06, 2025 | News

Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma

Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory C...

August 04, 2025 | News

Johor’s Healthcare Transformation: Billions Poured into Malaysia’s Life Sciences Engine (2022–2025)

Johor’s Healthcare & Life Sciences Investment Boom (2022–2025) Over the past three years, the southern Malaysian state of Johor has emerge...

July 30, 2025 | Report

Suzhou’s Kintor Pharma Reports Positive Phase II Results for KX-826 in AGA Trial, Clears Path for Phase III

Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and po...

July 28, 2025 | News

3 Trillion-Dollar Sectors, 2 Nations, 1 Game-Changing Deal: UK-India FTA and the Future of Life Sciences

UK-India FTA and Life Sciences: A Strategic Partnership for Growth The UK-India trade relationship has been evolving rapidly, culminating in a landmark Fr...

July 28, 2025 | Analysis

How Innovation Gaps in Biopharma Raise New Safety Concerns

The biopharmaceutical industry stands at the forefront of medical innovation and delivers remarkable advances in disease treatment and prevention. Breakthr...

July 24, 2025 | News

Stay Connected